```html

Zentel‑type Abdominal Pain (Functional Dyspepsia)

Overview

Functional dyspepsia (FD), sometimes described in the literature as “Zentel‑type abdominal pain,” is a chronic disorder of the upper gastrointestinal (GI) tract in which patients experience persistent or recurrent pain and discomfort in the upper abdomen without an identifiable structural or biochemical cause. The term “Zentel‑type” refers to a pattern of pain that is often episodic, mid‑epigastric, and may be provoked by meals, resembling the side‑effects sometimes reported with the anti‑parasitic medication Zentel (albendazole) in clinical case reports.

FD is one of the most common functional GI disorders worldwide. According to the Rome IV criteria, it affects approximately 10‑15 % of the adult population in both Western and Asian countries, with a slightly higher prevalence in women and in people aged 30‑50 years.<sup>1</sup> The condition can be chronic, lasting months to years, and significantly impairs quality of life, work productivity, and mental well‑being.<sup>2</sup>

Symptoms

Functional dyspepsia presents with a constellation of upper‑GI symptoms that may vary in intensity and frequency. The Rome IV classification separates FD into two sub‑types: post‑prandial distress syndrome (PDS) and epigastric pain syndrome (EPS). Many patients experience features of both.

Core symptom list

• Epigastric pain or burning – a dull, gnawing, or burning sensation located in the upper middle abdomen, often described as “heartburn‑like” but not relieved by antacids.
• Early satiety – feeling full after eating only a small amount of food.
• Post‑prandial fullness – persistent feeling of heaviness or bloating after a meal lasting for hours.
• Upper‑abdominal bloating – a sensation of abdominal distension without measurable swelling.
• Nausea – occasional or frequent, sometimes leading to vomiting.
• Belching or excessive gas – often accompanying meals.
• Loss of appetite – may be secondary to discomfort.

Associated but non‑specific features

• Fatigue, irritability, or difficulty concentrating (often linked to chronic pain).
• Anxiety or depressive symptoms – functional GI disorders have a strong brain‑gut connection.<sup>3</sup>
• Weight loss – usually mild and only when food intake is markedly reduced.

Symptoms must be present for **at least 3 months**, with an onset at least 6 months before diagnosis, and cannot be explained by an ulcer, cancer, gallbladder disease, pancreatitis, or other organic pathology.

Causes and Risk Factors

Functional dyspepsia is a “functional” disorder, meaning that the problem lies in the way the GI tract works rather than a structural lesion. The exact cause is multifactorial.

Pathophysiological mechanisms

• Impaired gastric accommodation – the stomach’s inability to relax and expand after a meal, leading to early satiety.
• Visceral hypersensitivity – heightened nerve sensitivity that makes normal gastric distension feel painful.
• Delayed gastric emptying (gastroparesis‑like) – food stays longer in the stomach, causing fullness and bloating.
• Altered gut microbiota – dysbiosis may affect motility and sensory pathways.<sup>4</sup>
• Low‑grade inflammation – subtle immune activation in the duodenum has been demonstrated in a subset of patients.
• Psychological factors – stress, anxiety, and depression can amplify perception of pain through the brain‑gut axis.

Risk factors

• Female sex (1.5‑2× higher risk)
• Age 30‑50 years (peak incidence)
• Smoking and excessive alcohol consumption
• High‑fat, low‑fiber diet
• History of gastro‑esophageal reflux disease (GERD) or irritable bowel syndrome (IBS)
• Psychological stress, anxiety disorders, or a history of childhood trauma
• Use of non‑steroidal anti‑inflammatory drugs (NSAIDs) – may aggravate symptoms but does not cause FD alone.

Diagnosis

Diagnosing functional dyspepsia is primarily a process of exclusion. Physicians combine a thorough clinical history with targeted investigations to rule out organic disease.

Step‑by‑step diagnostic approach

1. Medical History & Physical Exam – Detailed description of pain pattern, triggers, and associated symptoms; check for red‑flag signs (e.g., weight loss, vomiting, anemia).
2. Laboratory Tests – CBC, iron studies, vitamin B12, thyroid function, and H. pylori serology or stool antigen test.
3. Upper Endoscopy (EGD) – Recommended for patients >55 years, those with alarm features, or persistent symptoms despite initial therapy. Helps rule out ulcer, cancer, or gastritis.
4. Non‑invasive H. pylori testing – Eradication can improve symptoms in up to 30 % of FD patients.<sup>5</sup>
5. Abdominal Ultrasound – To exclude gallbladder disease or pancreatic pathology if clinically indicated.
6. Gastric Emptying Study – Scintigraphy or breath test; used when delayed gastric emptying is suspected.
7. Rome IV criteria – The gold‑standard symptom‑based diagnostic tool for functional GI disorders.

When all tests are normal and symptoms meet the Rome IV definition, a diagnosis of functional dyspepsia (Zentel‑type abdominal pain) is made.

Treatment Options

Treatment is individualized, often requiring a combination of pharmacologic therapy, dietary/lifestyle modification, and psychological support.

Pharmacologic therapies

• Proton Pump Inhibitors (PPIs) – Omeprazole, esomeprazole, or pantoprazole. Useful especially for EPS‑type pain. Typical dose: 20‑40 mg daily for 4‑8 weeks.
• H2‑Receptor Antagonists – Ranitidine (where available) or famotidine. Alternative for mild symptoms.
• Acid‑suppression plus prokinetics – Combination of a PPI with a prokinetic (e.g., domperidone, itopride) can improve post‑prandial fullness.
• Prokinetic agents – Metoclopramide, erythromycin (low‑dose), or newer agents like acotiamide (available in Japan/Europe). Aim to enhance gastric emptying.
• Tricyclic Antidepressants (TCAs) – Low‑dose amitriptyline or nortriptyline (10‑25 mg at night) for pain modulation, especially in EPS.
• Selective Serotonin Reuptake Inhibitors (SSRIs) / Serotonin‑Norepinephrine Reuptake Inhibitors (SNRIs) – For patients with co‑existent anxiety or depression.
• Rifaximin – A gut‑specific antibiotic shown to improve dyspeptic symptoms in a subset of patients, likely via modulation of microbiota.<sup>6</sup>
• Helicobacter pylori eradication therapy – Triple therapy (PPI + clarithromycin + amoxicillin) if infection is confirmed; can lead to symptom relief in ≈30 % of cases.

Procedural options

• Endoscopic pyloric dilation – Rarely used for refractory gastroparesis‑type symptoms.
• Psychological therapies – Cognitive‑behavioral therapy (CBT) or gut‑directed hypnotherapy, especially when stress amplifies symptoms.

Lifestyle and dietary measures

1. Eat smaller, more frequent meals (5‑6 small meals per day).
2. Chew food thoroughly; avoid rapid eating.
3. Identify and eliminate trigger foods – high‑fat, spicy, carbonated drinks, caffeine, and alcohol are common culprits.
4. Adopt a low‑FODMAP diet if bloating is prominent; evidence suggests benefit in functional GI disorders.
5. Maintain a healthy weight; obesity worsens gastroduodenal pressure.
6. Quit smoking and limit alcohol intake.
7. Stress‑reduction techniques – mindfulness, yoga, or regular aerobic exercise (≥150 min/week).

Living with Zentel‑type Abdominal Pain (Functional Dyspepsia)

While the condition can be chronic, many patients achieve good control with a systematic approach.

Practical daily‑management tips

• Symptom diary – Record meals, timing of pain, and severity (0‑10 scale). This helps identify patterns and guide therapy.
• Meal timing – Finish eating at least 2‑3 hours before lying down to reduce reflux‑related discomfort.
• Hydration – Sip water throughout the day, but limit large volumes during meals.
• Heat therapy – A warm compress on the epigastrium may soothe mild pain.
• Regular physical activity – Low‑impact exercise (walking, swimming) improves gastric motility.
• Mind‑body practices – Guided meditation or progressive muscle relaxation before meals can lower pain perception.
• Medication adherence – Take prescribed drugs exactly as directed; do not self‑adjust doses.
• Follow‑up schedule – Re‑evaluate with your clinician every 3‑6 months or sooner if symptoms change.

Prevention

Because FD is multifactorial, preventing its onset focuses on modifiable risk factors.

• Adopt a balanced diet rich in fiber, lean protein, and omega‑3 fatty acids.
• Limit intake of fried, fatty, and very spicy foods.
• Maintain a healthy body mass index (BMI 18.5‑24.9).
• Quit smoking and keep alcohol consumption moderate (≤1 drink/day for women, ≤2 for men).
• Manage stress proactively – therapy, exercise, or relaxation techniques.
• Screen and treat H. pylori infection when indicated.
• Avoid chronic use of NSAIDs; use acetaminophen for pain when appropriate.

Complications

While functional dyspepsia itself is not life‑threatening, untreated or poorly managed disease can lead to:

• Significant weight loss and malnutrition due to reduced food intake.
• Psychological distress – higher rates of anxiety, depression, and reduced quality of life.
• Medication overuse – frequent reliance on over‑the‑counter antacids or pain relievers can cause side effects.
• Development of secondary functional disorders – such as irritable bowel syndrome or functional heartburn.
• Healthcare utilization – increased doctor visits, diagnostic testing, and indirect costs (work absenteeism).

When to Seek Emergency Care

---

**References**

1. Mayo Clinic – Functional Dyspepsia
2. Impact of Functional Dyspepsia on Quality of Life – NCBI
3. Cleveland Clinic – Functional Dyspepsia
4. Gut Microbiota and Functional Dyspepsia – NCBI
5. CDC – Helicobacter pylori Diagnosis
6. Rifaximin for Functional Dyspepsia – Clinical Trial Review

```